翰思艾泰生物医药科技（武汉）股份有限公司（“翰思艾泰-B”，股票代码03378）于2026年7月16日发布翌日披露报表，披露其于当日于香港联交所场内回购15,600股H股普通股。该数量约占回购前公司已发行股份（不包括库存股份）总数134,136,830股的0.012%，回购价介乎每股28.94港元至29.68港元，合计耗资约45.38万港元。回购完成后，公司已发行股本变动为134,121,230股，库存股份增加至2,097,600股。
根据公告，股东大会已于2026年6月24日通过股份购回授权，总额度为13,469,683股。截至本次行动后，公司合计已回购575,600股，占授权通过当日已发行股份总数的0.4273%。公司同时披露剩余可回购股份数量为12,894,083股。
公司确认是次股份购回符合香港联合交易所有限公司证券上市规则和相关法律法规的要求，所有购回事宜已获得董事会正式批准。该公告由公司董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.